THE TAPE
RDNT · Medical Laboratories · $6.1B

RadNet, Inc. Common Stock

$76.89▲ +0.62%
Last close
Relative strength
72RS
of 99, against every stock▲ +13 on the month
Powering up
Unconfirmed
−10.6%
six months against Medical Laboratories
52-week range
−10.4%
from the high
$50.82$85.84
Setup
vcpclimbing
−3.6%
against the pivot at $79.77
No report date on the calendar.
Growth REALProof SHOWN
Quarter to Sep 30, revenue +22% on a year ago
11/16 O 77.00 H 77.00 L 75.50 Vol 565.0K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS72
vs pivot−3.61%
Tightening1.17×
Dry-up1.37×
Up/down vol0.02
From high10%
failed pokeclimbing8 of 9checks
Previous breakout stopped out ▼ −8.29% in Aug
Powering up
Support and resistance
Support below
$73.68
-4.2% · tested 3× · last 54 sessions ago
Resistance above
$78.01
+1.5% · tested 5× · last 52 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 7.2 weeks and fell 17% from its ceiling at its deepest. The pivot is $79.77, and the stock closed 3.6% below it. Its relative strength rating is 72.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
+9.1%
Three months against its industry
-7.6%
Six months against its industry
-10.6%

Read against an equal-weighted index of Medical Laboratories, which is +58.5% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 5.8% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.4B
+22.1% year on year
Operating margin
3.1%
Net margin
-0.9%
Free cash flow
$347.8M
5.7% of market cap
Price to sales
2.54×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 8
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$638.3M
+2.5% QoQ · +22.1% YoY
Gross margin
—
Net income
$4.2M
Positive
Free cash flow
$90.6M
Cash generating

What the numbers say

  • Good: Revenue +22.1% year over year, +2.5% on the quarter
  • Good: Profitable: net income $4M, operating margin 4.7%
  • Good: Cash generating: operating cash flow $91M, free cash flow $91M
  • Net debt $575M · cash $751M
Revenue by quarter
Free cash flow
Net income
shares +2.3% in a year · net debt $574.7M

What is not obvious

  • Weak: Interest $21M takes 68% of operating income $30M
Final read
Growth: REAL · Economic proof: SHOWN
Key question: Does the next quarter repeat this one?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

No tracked fund holds it now at the end of Q3 2026.

Last quarter: 2 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Earnings comingEvent · 2026-11-07
reports 2026-11-08
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Unusual volumeTape · 2026-11-07
3.3 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-05
+9.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-05
5.1 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Earnings date movedEvent · 2026-11-03
2026-11-05 -> 2026-11-08
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-03
above 20d & 50d on 1.7x volume at 73.10
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-28
above 20d & 50d on 2.1x volume at 73.54
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Red flag in a filingFiling · 2026-10-27
material weakness;non-reliance
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
5
$6,490,718 total

Sold: Patel Mital, SWARTZ DAVID L, Wesdorp Cornelis, Forthuber Stephen M.

Not counted above: 6 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-12 Patel Mital · EVP, Chief Operating Officergift640
2026-11-11 Patel Mital · EVP, Chief Operating Officersell44,661$3,506,335
2026-06-18 SWARTZ DAVID L · Directorsell2,699$145,449
2026-06-16 Wesdorp Cornelis · Pres & CEO, Digital Healthsell4,750$276,023
2026-06-16 Berger Howard G · President, CEO, Directorgift90
2026-06-15 Forthuber Stephen M · Pres & CEO-Eastern Operationssell24,214$1,399,327
2026-06-15 Forthuber Stephen M · Pres & CEO-Eastern Operationssell19,853$1,163,584
2026-06-02 SWARTZ DAVID L · Directoraward2,946

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

8 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy2
Buy5
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
7w · 17%

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
RadNet, Inc. Common Stock (RDNT) — The Tape